Skip to main content

Clinical trial CONTACT 02

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer

Organ prostate
Trial status Trial closed for recruitment
Trial type
Interventional with experimental drug
Phase Trial phase 3
Academic trial Non
Sponsor Exelixis
EudraCT Identifier 2020-000348-77
Last update